Masimo Corp (MASI) 24.49 $MASI
Masimo Receives 2014 Zenith Award at the American Association of Respiratory Care Congress
Marketwired - Wed Dec 10, 7:02AM CST
Masimo (NASDAQ: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-through Motion and Low Perfusion(TM) pulse oximetry, announced today that it has received the prestigious Zenith Award for equipment and service excellence from the American Association of Respiratory Care (AARC) at the 60th Annual AARC Congress in Las Vegas, Nev.
MASI: 24.49 (-0.42)
Masimo iSpO2(TM) Pulse Oximeter Featured in Fitness Book by Tour de France Champion Greg LeMond
Marketwired - Thu Dec 04, 10:01AM CST
Masimo (NASDAQ: MASI) today announced that its award-winning iSpO2(TM) pulse oximeter is featured in the upcoming book "The Science of Fitness: Power, Performance, and Endurance," by three-time Tour de France champion Greg LeMond and co-author interventional radiologist Dr. Mark Hom, available at Amazon.com and the Elsevier Store.
MASI: 24.49 (-0.42)
Masimo's Radius-7 Monitor Gets FDA Nod, Rivalry Intensifies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 6:00PM CST
Manufacturer of patient monitoring products, Masimo Corp. (MASI) recently announced Food and Drug Administration (FDA)'s clearance of the company's Radius-7 wireless monitor.
BABY: 34.84 (-0.41), MASI: 24.49 (-0.42), CASM: 1.77 (-0.03), COV: 100.49 (-1.36)
FDA clears Masimo wireless patient monitor
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 2:39PM CST
MASI: 24.49 (-0.42)
Masimo Announces FDA 510(k) Clearance of Radius-7(TM)-First rainbow(R) SET(R) Noninvasive Wearable, Wireless Monitor for Root(R)
Marketwire Canada - Mon Dec 01, 12:22PM CST
Masimo (NASDAQ: MASI) today announced FDA 510(k) clearance of Radius-7(TM) for the Root(R) patient monitoring and connectivity platform, the first and only wearable, wireless monitor with Masimo's breakthrough rainbow(R) SET(R) technology, offering patients continuous monitoring with freedom of movement.
MASI: 24.49 (-0.42)
Masimo Announces FDA 510(k) Clearance of Radius-7(TM) -- First rainbow(R) SET(R) Noninvasive Wearable, Wireless Monitor for Root(R)
Marketwired - Mon Dec 01, 12:21PM CST
Masimo (NASDAQ: MASI) today announced FDA 510(k) clearance of Radius-7(TM) for the Root(R) patient monitoring and connectivity platform, the first and only wearable, wireless monitor with Masimo's breakthrough rainbow(R) SET(R) technology, offering patients continuous monitoring with freedom of movement.
MASI: 24.49 (-0.42)
Masimo to Present at 26th Annual Piper Jaffray Health Care Conference
Marketwired - Wed Nov 19, 4:01PM CST
Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the 26th Annual Piper Jaffray Health Care Conference at the New York Palace Hotel in New York on Tuesday, December 2, 2014, at 1:00 p.m. Eastern Time. A live audiocast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the audiocast will be available following the live presentation.
MASI: 24.49 (-0.42)
Masimo Earnings Hindsight: Up 13.7% in Last 19 Days (MASI)
Comtex SmarTrend(R) - Mon Nov 17, 1:11PM CST
When Masimo (NASDAQ:MASI) reported earnings 19 days ago on October 29th, 2014, analysts, on average, expected the company to report earnings of $0.25 on sales of $144.0 million. Masimo actually reported earnings of $0.27 per share on sales of $144.1 million, beating EPS estimates by $0.02 and matching revenue estimates. Since the company's report, shares of Masimo have risen from $23.23 to $26.42, representing a gain of 13.7% in the past 19 days.
MASI: 24.49 (-0.42)
Update: Masimo Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Tue Nov 11, 1:37PM CST
MASI: 24.49 (-0.42)
Earnings Flashback: Since Reporting Quarterly Results 1 Week Ago Masimo Is Up 9.9% (MASI)
Comtex SmarTrend(R) - Mon Nov 10, 12:10PM CST
When Masimo (NASDAQ:MASI) reported earnings a week ago on October 29th, 2014, analysts, on average, expected the company to report earnings of $0.25 on sales of $144.0 million. The company actually reported EPS of $0.27 on sales of $144.1 million, beating EPS estimates by $0.02 and matching revenue estimates. Since the company's report, shares of Masimo have risen from $23.23 to $25.52, representing a gain of 9.9% in the past 12 days.
MASI: 24.49 (-0.42)
Masimo (MASI) Upgraded From Hold to Buy
at The Street - Wed Nov 05, 8:13AM CST
Masimo MASI has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:
MASI: 24.49 (-0.42)
New Clinical Study Shows Accuracy of Masimo Noninvasive Spot-Check Hemoglobin (SpHb(R)) in Trauma Patients
Marketwired - Wed Nov 05, 7:05AM CST
Masimo (NASDAQ: MASI) announced today that a new clinical study published in the Journal of the American College of Surgeons showed that noninvasive spot-check hemoglobin (SpHb) measurements had good correlation with invasive laboratory hemoglobin measurements in trauma patients with the potential to speed clinical decision-making to improve care, patient safety, and cost of care.(1)
MASI: 24.49 (-0.42)
Masimo Beats Q3 Earnings Estimates, Cuts Revenue Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 12:49PM CDT
Masimo Corp (MASI) reported earnings of 27 cents per share in the third quarter of 2014, which beat the Zacks Consensus Estimate by a couple of cents
ATEC: 1.28 (-0.01), MASI: 24.49 (-0.42), CYNO: 28.70 (-0.04), ELMD: 2.33 (-0.05)
Masimo updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 11:30AM CDT
MASI: 24.49 (-0.42)
Shares of MASI Down 10.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Oct 30, 10:02AM CDT
SmarTrend identified a Downtrend for Masimo (NASDAQ:MASI) on April 8th, 2014 at $26.46. In approximately 7 months, Masimo has returned 10.26% as of today's recent price of $23.74.
MASI: 24.49 (-0.42)
Masimo beats 3Q profit forecasts
Automated Insights - Thu Oct 30, 4:04AM CDT
IRVINE, Calif. (AP) _ Masimo Corp. (MASI) on Thursday reported profit of $14.9 million in its third quarter.
MASI: 24.49 (-0.42)
Masimo's (MASI) CEO Joe Kiani on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 29, 8:50PM CDT
MASI: 24.49 (-0.42)
Masimo beats by $0.02, revenue in-line
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 3:33PM CDT
MASI: 24.49 (-0.42)
Masimo Reports Third Quarter 2014 Financial Results
Marketwired - Wed Oct 29, 3:12PM CDT
Masimo (NASDAQ: MASI)
MASI: 24.49 (-0.42)
Masimo Has Returned 17.3% Since SmarTrend Recommendation (MASI)
Comtex SmarTrend(R) - Thu Oct 23, 9:26AM CDT
SmarTrend identified a Downtrend for Masimo (NASDAQ:MASI) on April 8th, 2014 at $26.46. In approximately 7 months, Masimo has returned 17.33% as of today's recent price of $21.87.
MASI: 24.49 (-0.42)
Masimo Receives 2014 Zenith Award at the American Association of Respiratory Care Congress
Marketwired - Wed Dec 10, 7:02AM CST
Masimo (NASDAQ: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-through Motion and Low Perfusion(TM) pulse oximetry, announced today that it has received the prestigious Zenith Award for equipment and service excellence from the American Association of Respiratory Care (AARC) at the 60th Annual AARC Congress in Las Vegas, Nev.
MASI: 24.49 (-0.42)
Masimo iSpO2(TM) Pulse Oximeter Featured in Fitness Book by Tour de France Champion Greg LeMond
Marketwired - Thu Dec 04, 10:01AM CST
Masimo (NASDAQ: MASI) today announced that its award-winning iSpO2(TM) pulse oximeter is featured in the upcoming book "The Science of Fitness: Power, Performance, and Endurance," by three-time Tour de France champion Greg LeMond and co-author interventional radiologist Dr. Mark Hom, available at Amazon.com and the Elsevier Store.
MASI: 24.49 (-0.42)
Masimo's Radius-7 Monitor Gets FDA Nod, Rivalry Intensifies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 6:00PM CST
Manufacturer of patient monitoring products, Masimo Corp. (MASI) recently announced Food and Drug Administration (FDA)'s clearance of the company's Radius-7 wireless monitor.
BABY: 34.84 (-0.41), MASI: 24.49 (-0.42), CASM: 1.77 (-0.03), COV: 100.49 (-1.36)
FDA clears Masimo wireless patient monitor
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 2:39PM CST
MASI: 24.49 (-0.42)
Masimo Announces FDA 510(k) Clearance of Radius-7(TM)-First rainbow(R) SET(R) Noninvasive Wearable, Wireless Monitor for Root(R)
Marketwire Canada - Mon Dec 01, 12:22PM CST
Masimo (NASDAQ: MASI) today announced FDA 510(k) clearance of Radius-7(TM) for the Root(R) patient monitoring and connectivity platform, the first and only wearable, wireless monitor with Masimo's breakthrough rainbow(R) SET(R) technology, offering patients continuous monitoring with freedom of movement.
MASI: 24.49 (-0.42)
Masimo Announces FDA 510(k) Clearance of Radius-7(TM) -- First rainbow(R) SET(R) Noninvasive Wearable, Wireless Monitor for Root(R)
Marketwired - Mon Dec 01, 12:21PM CST
Masimo (NASDAQ: MASI) today announced FDA 510(k) clearance of Radius-7(TM) for the Root(R) patient monitoring and connectivity platform, the first and only wearable, wireless monitor with Masimo's breakthrough rainbow(R) SET(R) technology, offering patients continuous monitoring with freedom of movement.
MASI: 24.49 (-0.42)
Masimo to Present at 26th Annual Piper Jaffray Health Care Conference
Marketwired - Wed Nov 19, 4:01PM CST
Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the 26th Annual Piper Jaffray Health Care Conference at the New York Palace Hotel in New York on Tuesday, December 2, 2014, at 1:00 p.m. Eastern Time. A live audiocast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the audiocast will be available following the live presentation.
MASI: 24.49 (-0.42)
Masimo Earnings Hindsight: Up 13.7% in Last 19 Days (MASI)
Comtex SmarTrend(R) - Mon Nov 17, 1:11PM CST
When Masimo (NASDAQ:MASI) reported earnings 19 days ago on October 29th, 2014, analysts, on average, expected the company to report earnings of $0.25 on sales of $144.0 million. Masimo actually reported earnings of $0.27 per share on sales of $144.1 million, beating EPS estimates by $0.02 and matching revenue estimates. Since the company's report, shares of Masimo have risen from $23.23 to $26.42, representing a gain of 13.7% in the past 19 days.
MASI: 24.49 (-0.42)
Update: Masimo Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Tue Nov 11, 1:37PM CST
MASI: 24.49 (-0.42)
Earnings Flashback: Since Reporting Quarterly Results 1 Week Ago Masimo Is Up 9.9% (MASI)
Comtex SmarTrend(R) - Mon Nov 10, 12:10PM CST
When Masimo (NASDAQ:MASI) reported earnings a week ago on October 29th, 2014, analysts, on average, expected the company to report earnings of $0.25 on sales of $144.0 million. The company actually reported EPS of $0.27 on sales of $144.1 million, beating EPS estimates by $0.02 and matching revenue estimates. Since the company's report, shares of Masimo have risen from $23.23 to $25.52, representing a gain of 9.9% in the past 12 days.
MASI: 24.49 (-0.42)
Masimo (MASI) Upgraded From Hold to Buy
at The Street - Wed Nov 05, 8:13AM CST
Masimo MASI has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:
MASI: 24.49 (-0.42)
New Clinical Study Shows Accuracy of Masimo Noninvasive Spot-Check Hemoglobin (SpHb(R)) in Trauma Patients
Marketwired - Wed Nov 05, 7:05AM CST
Masimo (NASDAQ: MASI) announced today that a new clinical study published in the Journal of the American College of Surgeons showed that noninvasive spot-check hemoglobin (SpHb) measurements had good correlation with invasive laboratory hemoglobin measurements in trauma patients with the potential to speed clinical decision-making to improve care, patient safety, and cost of care.(1)
MASI: 24.49 (-0.42)
Masimo Beats Q3 Earnings Estimates, Cuts Revenue Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 12:49PM CDT
Masimo Corp (MASI) reported earnings of 27 cents per share in the third quarter of 2014, which beat the Zacks Consensus Estimate by a couple of cents
ATEC: 1.28 (-0.01), MASI: 24.49 (-0.42), CYNO: 28.70 (-0.04), ELMD: 2.33 (-0.05)
Masimo updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 11:30AM CDT
MASI: 24.49 (-0.42)
Shares of MASI Down 10.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Oct 30, 10:02AM CDT
SmarTrend identified a Downtrend for Masimo (NASDAQ:MASI) on April 8th, 2014 at $26.46. In approximately 7 months, Masimo has returned 10.26% as of today's recent price of $23.74.
MASI: 24.49 (-0.42)
Masimo beats 3Q profit forecasts
Automated Insights - Thu Oct 30, 4:04AM CDT
IRVINE, Calif. (AP) _ Masimo Corp. (MASI) on Thursday reported profit of $14.9 million in its third quarter.
MASI: 24.49 (-0.42)
Masimo's (MASI) CEO Joe Kiani on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 29, 8:50PM CDT
MASI: 24.49 (-0.42)
Masimo beats by $0.02, revenue in-line
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 3:33PM CDT
MASI: 24.49 (-0.42)
Masimo Reports Third Quarter 2014 Financial Results
Marketwired - Wed Oct 29, 3:12PM CDT
Masimo (NASDAQ: MASI)
MASI: 24.49 (-0.42)
Masimo Has Returned 17.3% Since SmarTrend Recommendation (MASI)
Comtex SmarTrend(R) - Thu Oct 23, 9:26AM CDT
SmarTrend identified a Downtrend for Masimo (NASDAQ:MASI) on April 8th, 2014 at $26.46. In approximately 7 months, Masimo has returned 17.33% as of today's recent price of $21.87.
MASI: 24.49 (-0.42)
